Recombinant Super-compound Interferon clinical trials
How each study uses Recombinant Super-compound Interferon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Recombinant Super-compound Interferon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2013 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Sichuan Huiyang Life Science and Technology Corporation (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Recombinant Super-compound Interferon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal CancerNot yet recruitingPhase 2Sichuan Huiyang Life Science and Technology CorporationNCT07662278Written as Recombinant Super-Compound Interferon (rSIFN-co)
- rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19CompletedPhase 2Sichuan Huiyang Life Science and Technology CorporationNCT05485584Written as rSIFN-co Nasal Spray
- Study of rSIFN-co for Patients With Advanced Solid TumorsTerminatedPhase 1Sichuan Huiyang Life Science and Technology CorporationNCT02464007Written as rSIFN-co
- A Study of rSIFN-co in Subjects With Advanced Solid TumorsCompletedPhase 1Sichuan Huiyang Life Science and Technology CorporationNCT02387307Written as rSIFN-co